Abstract| Volume 14, ISSUE 7, SUPPLEMENT , S144, September 2008

Stem Cell Therapy : Hype or Hope ?

  • Philippe Menasché
    Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Department of Cardiovascular Surgery; Université Paris Descartes, Faculté de Médecine, Paris, France
    Search for articles by this author
      Cell therapy trials for “regenerating” chronically failing hearts have entailed the use of bone marrow-derived cells and skeletal myoblasts. In the case of bone marrow cells, surgical injections of the mononuclear fraction combined with coronary artery bypass surgery have failed to show any substantial benefit. More successful outcomes have been reported after catheter transfer of these cells or intraoperative epicardial injections of CD133+ progenitors, probably because of angiogenesis. In the case of skeletal myoblasts, the surgical MAGIC trial has not achieved its primary efficacy end point but the highest dose of myoblasts resulted in a significant anti-remodeling effect compared with the placebo group. The results of the catheter-based myoblast delivery trials have been more disappointing.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Cardiac Failure
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect